128 related articles for article (PubMed ID: 7644663)
21. Anaphylaxis after first exposure to gadoterate meglumine: a case report and literature review.
Bianchi L; Hansel K; Marietti R; Tramontana M; Stingeni L
J Allergy Clin Immunol Pract; 2018; 6(6):2124-2126. PubMed ID: 29559210
[No Abstract] [Full Text] [Related]
22. Anaphylactic shock induced by gadoterate meglumine (DOTAREM).
Beaudouin E; Kanny G; Blanloeil Y; Guilloux L; Renaudin JM; Moneret-Vautrin DA
Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):382-5. PubMed ID: 14768523
[TBL] [Abstract][Full Text] [Related]
23. Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections.
McDonald JS; Hunt CH; Kolbe AB; Schmitz JJ; Hartman RP; Maddox DE; Kallmes DF; McDonald RJ
Radiology; 2019 Sep; 292(3):620-627. PubMed ID: 31264948
[TBL] [Abstract][Full Text] [Related]
24. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
25. Worldwide clinical safety assessment of gadoteridol injection: an update.
Runge VM; Parker JR
Eur Radiol; 1997; 7 Suppl 5():243-5. PubMed ID: 9370551
[TBL] [Abstract][Full Text] [Related]
26. How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease?
Perazella MA
Clin J Am Soc Nephrol; 2008 May; 3(3):649-51. PubMed ID: 18385396
[No Abstract] [Full Text] [Related]
27. Nephrogenic systemic fibrosis in Japan: advisability of keeping the administered dose as low as possible.
Tsushima Y; Takahashi-Taketomi A; Endo K
Radiology; 2008 Jun; 247(3):915-6. PubMed ID: 18487548
[No Abstract] [Full Text] [Related]
28. Safety and tolerance after intravenous administration of 0.3 mmol/kg Gd-DTPA. Results of a randomized, controlled clinical trial.
Niendorf HP; Haustein J; Louton T; Beck W; Laniado M
Invest Radiol; 1991 Nov; 26 Suppl 1():S221-3; discussion S232-5. PubMed ID: 1808134
[No Abstract] [Full Text] [Related]
29. Incidence and severity of acute adverse reactions to four different gadolinium-based MR contrast agents.
Okigawa T; Utsunomiya D; Tajiri S; Okumura S; Sasao A; Wada H; Oda S; Arimura H; Hayashida E; Urata J; Yamashita Y
Magn Reson Med Sci; 2014; 13(1):1-6. PubMed ID: 24492735
[TBL] [Abstract][Full Text] [Related]
30. [Nephrotoxicity of contrast media in magnetic resonance tomography (MRI)].
Heuck A; Reiser M
Internist (Berl); 1997 Dec; 38(12):1234-5. PubMed ID: 9465330
[No Abstract] [Full Text] [Related]
31. Safety of ProHance in special populations.
Yoshikawa K; Davies A
Eur Radiol; 1997; 7 Suppl 5():246-50. PubMed ID: 9370552
[TBL] [Abstract][Full Text] [Related]
32. [The Grenelle of MR contrast agents?].
Clément O
J Radiol; 2007 Nov; 88(11 Pt 1):1663. PubMed ID: 18065924
[No Abstract] [Full Text] [Related]
33. Epinephrine dose for treating contrast material-induced reactions.
Winter TC; Abraham RJ; Lightfoot CB; Kapur S
Radiology; 2009 Nov; 253(2):573; author reply 573. PubMed ID: 19864534
[No Abstract] [Full Text] [Related]
34. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update.
Kanal E; Broome DR; Martin DR; Thomsen HS
Radiology; 2008 Jan; 246(1):11-4. PubMed ID: 17855656
[No Abstract] [Full Text] [Related]
35. Gadolinium-Induced Fibrosis.
Todd DJ; Kay J
Annu Rev Med; 2016; 67():273-91. PubMed ID: 26768242
[TBL] [Abstract][Full Text] [Related]
36. Anaphylactoid reactions to i.v. gadopentetate dimeglumine.
Tishler S; Hoffman JC
AJNR Am J Neuroradiol; 1990; 11(6):1167; discussion 1168-9. PubMed ID: 2124049
[No Abstract] [Full Text] [Related]
37. Severe anaphylactoid reaction to Gd-DTPA.
Lufkin RB
Radiology; 1990 Sep; 176(3):879. PubMed ID: 2389057
[No Abstract] [Full Text] [Related]
38. Safety of magnetic resonance imaging contrast agents.
Shellock FG; Kanal E
J Magn Reson Imaging; 1999 Sep; 10(3):477-84. PubMed ID: 10508312
[TBL] [Abstract][Full Text] [Related]
39. Type of MRI contrast, tissue gadolinium, and fibrosis.
Do C; Barnes JL; Tan C; Wagner B
Am J Physiol Renal Physiol; 2014 Oct; 307(7):F844-55. PubMed ID: 25100280
[TBL] [Abstract][Full Text] [Related]
40. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
